Momenta Pharmaceuticals, Inc. (MNTA)

Ganndalf (< 20) Submitted: 6/14/07 11:49 AM : Start Price: $15.88 MNTA Score: -2.33

Honestly, I know precious little about Momenta, but here's a few things I do know:

They are very close to their 52-week low right now, which more often than not can be a good sign of a bargain buy.

Looks like a waiting game for its lead compound right now, here's what Brian Lawler says,

"Momenta isn't the only drugmaker expecting approval of its generic enoxaparin product. Competitor Watson Pharmaceuticals (NYSE: WPI) has been guiding investors to expect approval of its product sometime this year as well. Having to share generic Lovenox sales with other competitors like Watson or Teva (Nasdaq: TEVA) would obviously not be a desirable outcome for Momenta, and would call into doubt the superiority of its drug characterization technology and its competitive advantage."

Momenta is a RB selection, and it was in the running for best drug stock of 2007. Karl Thiel wrote an excellent little article regarding the merits of this little company:

http://www.fool.com/investing/high-growth/2007/01/19/the-best-drug-stock-for-2007-momenta.aspx

Here's a short excerpt:

"Momenta is what you might call a biogenerics company -- an industry niche that barely exists today, but will be a big deal in the not-so-distant future. Complex biotechnology drugs aren't often as easy to duplicate as conventional pills, but to the companies that can pass the technological, regulatory, and legal hurdles, great rewards await. Momenta, for example, has made a copycat of the Sanofi-Aventis (NYSE: SNY) drug Lovenox, a blood thinner that brought in a cool $2.7 billion in 2005 sales and could top $3 billion in 2006. Lots of companies would like to sweep in and take a chunk of that market, but they must first prove that their version of the low-molecular-weight heparin is essentially identical. Since Lovenox is a complex mixture of carbohydrate fragments, that's a tall order -- one that Momenta claims it has tackled, and one that competing generic companies probably can't match with current technology."

Report this Post Replies: 0 | Reply